Keywords: texas, submits, corrected, amendment, novastan, nda, following
Texas submits corrected amendment to Novastan NDA
Article | 26 August 1999
Following discussions with the US federal regulatory agency, TexasBiotechnology has submitted a corrected amendment to its Novastan (argatroban) New Drug ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
